Every 8-K that Pulmonx Corporation (LUNG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow LUNG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LUNG filings page.
Pulmonx Corporation reported second-quarter 2026 results with worldwide revenue of $22.8 million, a 5% year-over-year decline, including U.S. revenue of $14.2 million and international revenue of $8.6 million. International revenue excluding China grew 12% year over year.
Gross profit was $17.7 million, yielding a record 78% gross margin, up from 72% a year earlier. Operating expenses fell 16% to $26.8 million, helping reduce net loss to $10.1 million, or $0.24 per share, and cut Adjusted EBITDA loss to $5.1 million, a 39% reduction.
Cash and cash equivalents were $55.8 million as of June 30, 2026. For full-year 2026, the company continues to expect revenue of $90 million to $92 million, gross margin of about 76%, operating expenses of $109 million to $111 million, and an approximately $23 million decrease in cash, cash equivalents and marketable securities.
Pulmonx Corporation reported the results of its 2026 annual meeting of stockholders. A total of 32,645,270 shares were present or represented by proxy, representing approximately 77.29% of the 42,237,203 shares outstanding and entitled to vote as of April 7, 2026.
Stockholders elected three Class III directors — Thomas W. Burns, Georgia Garinois-Melenikiotou, and Dana G. Mead, Jr. — to serve until the 2029 annual meeting and until their successors are elected and qualified.
Stockholders also ratified the appointment of BDO USA, P.C. as independent registered public accounting firm for the year ending December 31, 2026, and approved, on a non-binding advisory basis, the company’s executive compensation as described in the proxy statement.
Pulmonx Corporation reported first-quarter 2026 results with lower revenue but improved margins and a slightly smaller loss. Revenue was $20.6 million, down 9% from $22.5 million a year earlier, with U.S. revenue of $13.3 million and international revenue of $7.3 million. International sales were hurt by a lack of sales into China while the company awaits renewal of its registration certificate; excluding China, international revenue grew 22%.
Gross profit was $16.0 million and gross margin improved to 78% from 73% in 2025. Operating expenses fell 6% to $29.0 million. Net loss narrowed to $13.7 million, or $0.33 per share, from $14.4 million, or $0.36 per share. Adjusted EBITDA loss was $8.5 million, and cash and cash equivalents totaled $61.6 million as of March 31, 2026.
Pulmonx reaffirmed its 2026 outlook, continuing to expect full-year revenue of $90–$92 million, gross margin of about 75%, and total operating expenses of $113–$115 million, including roughly $19 million of stock-based compensation. Management highlighted refreshed U.S. commercial strategies, a fully staffed global sales organization, and a recently refinanced 5-year interest-only credit facility maturing in 2031.
Pulmonx Corporation entered into a new senior secured term loan facility of up to $60.0 million with Perceptive Credit Holdings V, LP. The company drew an initial $40.0 million on closing, with two additional $10.0 million tranches available if specified trailing twelve‑month revenue targets of $92.5 million and $100.0 million are met by September 30, 2027 and December 31, 2027, respectively.
The loan matures on March 2, 2031 and bears interest at one‑month term SOFR (floored at 3.75%) plus a 7.00% margin, with the option to pay up to 2.00% of the margin in kind for 36 months. Pulmonx must maintain at least $4.0 million in liquidity and meet ongoing revenue covenants, and its obligations are secured by a first‑priority lien on substantially all assets of the company and certain subsidiaries.
In connection with the financing, Pulmonx issued Perceptive a warrant to purchase 1,000,000 common shares at an exercise price of $1.92 per share, and will issue additional warrants tied to any future delayed‑draw loans. The company also fully repaid and terminated its prior credit facility with Canadian Imperial Bank of Commerce without early termination fees.
Pulmonx Corporation reported mixed fourth quarter and full-year 2025 results while issuing cautious 2026 guidance. Full-year 2025 revenue reached $90.5 million, up 8% from 2024, driven by 23% international growth, while U.S. revenue grew 1%. Fourth quarter revenue was $22.6 million, down 5% year over year, as U.S. sales declined 11% but international revenue rose 8%.
Profitability metrics improved modestly. Full-year gross profit was $67.1 million with a 74% gross margin, and fourth quarter gross margin increased to 78%. The company narrowed its net loss to $54.0 million for 2025, or $1.33 per share, from a $56.4 million loss in 2024, and reduced its adjusted EBITDA loss to $30.6 million.
Pulmonx ended 2025 with $69.8 million in cash, cash equivalents, and marketable securities, down about $32 million over the year. It refinanced its debt with a new 5-year interest-only credit facility providing up to $60 million and extending maturity to 2031, and executed a cost restructuring to lower operating expenses. For 2026, the company guides revenue to $90–$92 million, gross margin around 75%, operating expenses of $113–$115 million (including about $21 million of stock-based compensation), and expects cash and investments to decline by roughly $23 million, assuming no further credit facility drawdowns.
Pulmonx (LUNG) announced leadership changes and compensation terms. Steven S. Williamson resigned as President, CEO, and director effective October 27, 2025. He will receive $600,000 over 12 months and COBRA reimbursement for up to 14 months, and will consult through December 1, 2025 for a $50,000 fee with continued equity vesting until that date.
The Board appointed Glendon E. French as President and CEO effective October 27, 2025, continuing as a Class I director. His offer includes a $625,000 base salary, a target bonus equal to 100% of salary, a 1,200,000-share RSU grant vesting quarterly over three years, and an 800,000-share PSU grant that vests upon time-based milestones and a performance condition of a $4.00 average closing price over 60 consecutive trading days.
Mehul Joshi resigned as CFO effective October 27, 2025 and will receive $347,625 over nine months, COBRA reimbursement up to 11 months, and a $30,000 consulting fee with equity vesting through December 1, 2025. Derrick Sung, Ph.D., was appointed COO and CFO effective November 3, 2025, with a $500,000 base salary, a 60% target bonus, a 1,200,000-share RSU, and a 400,000-share PSU with the same $4.00 performance condition.